BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Last trade$1.21
Day change+$0.06 (+5.22%)
Day range$1.18 – $1.29
Volume28,672
Market cap$6M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BLRX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for BLRX.
Recent news
Company coverage with links to the original publishers.
Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.
BioLineRx reported Q1 2026 results with a net loss of $2.6 million versus net income of $5.1 million in Q1 2025. The company initiated a Phase I/IIa trial for GLIX1 in glioblastoma with first patient dosed at NYU Langone Health, supported by preclinical data showing dose-dependent tumor growth inhibition. APHEXDA royalty revenues increased to $0.5 million from $0.3 million as Ayrmid's sales grew to $2.5 million. The company ended the quarter with $17.4 million in cash, sufficient to fund operations into H1 2027.
BioLineRx, a commercial-stage biopharmaceutical company, announced that it will release its Q3 2024 financial results on November 25, 2024, and host a conference call the same day.
HC Wainwright & Co. has decided to maintain its Buy rating of BioLine Rx (NASDAQ:BLRX) and raise its price target from $19.00 to $21.00.
Shares of BioLine Rx are trading up 11.36% over the last 24 hours, at $1.96 per share.
A move to $21.00 would account for a 971.43% increase from the current share price.
About BioLine Rx
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in ...Full story available on Benzinga.com
B of A Securities raised the price target for Unity Software Inc. (NYSE: U) from $46 to $56. B of A Securities analyst Ryan Gee upgraded the stock from Neutral to Buy. Unity Software shares fell 3% to close at $35.71 on Thursday.
Truist Securities boosted Vornado Realty Trust (NYSE: VNO) price target from $22 to $27. Truist Securities analyst Michael Lewis downgraded the stock from Buy to Hold. Vornado Realty Trust shares gained 2.9% to close at $25.24 on Thursday.
Needham cut the price target for STAAR Surgical Company (NASDAQ: STAA) from $54 to $52. Needham analyst David Saxon maintained a Buy rating. STAAR Surgical shares fell 1.8% to $42.08 in pre-market trading.
HC Wainwright & Co. raised the price target for BioLineRx Ltd. (NASDAQ: BLRX) ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.